Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings

(Thomson Reuters ONE) -


BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE March 10, 2010 at 4.30 p.m.


Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act relating to decrease in holdings

Biotie Therapies Corp. ("Company") has gained knowledge of the notification
regarding the following changes in holdings in accordance with Chapter 2,
Section 9 of the Finnish Securities Markets Act (decrease below 1/20 of total
number of shares).

TVM Life Science Ventures VI GmbH & Co. KG has notified that their holdings has
decreased below 5% to 4.86% of total number of shares in the Company.

The holdings in accordance with Chapter 2, Section 9 of the Finnish Securities
Markets Act of which the Company has gained knowledge is described below.


Name of the shareholder % of shares


TVM Life Science Ventures VI GmbH & Co. KG 4.86%
Register.no.HRA 84941



The registered number of shares in Biotie Therapies Corp. is 158,752,560 and the
number of voting rights attached to the shares amounts to 158,752,560. Of these
shares 463.255 are owned by the Company.

In Turku, 10 March 2010

Biotie Therapies Corp.
Timo Veromaa, President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.com


www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media





[HUG#1392564]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 10.03.2010 - 15:33 Uhr
Sprache: Deutsch
News-ID 17284
Anzahl Zeichen: 0

contact information:
Town:

Turku

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 250 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings"
steht unter der journalistisch-redaktionellen Verantwortung von

Biotie Therapies Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dep ...

TURKU, FINLAND -- (Marketwired) -- 05/10/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 May 2013 at 9.00 a.m.Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The Nat ...

Biotie: Selincro Launched in the United Kingdom ...

TURKU, FINLAND -- (Marketwired) -- 05/06/13 -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, B ...

Biotie: Selincro Launched in First European Markets ...

TURKU, FINLAND -- (Marketwired) -- 04/22/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 April 2013 at 9:00 a.m.Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started launching Selincro™ in the first European markets, ...

Alle Meldungen von Biotie Therapies Oyj